EUVIMEDEUVIMED entdecken
Crossref

Macrolide-resistant Mycoplasma pneumoniae: laboratory diagnosis and epidemiology

Kuenyoul Park, Heungsup Sung

Annals of Clinical Microbiology · 20.09.2026 · 29 (3) · 10-10

DOI: 10.5145/acm.2026.29.3.10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical Microbiology, online erschienen am 20.09.2026. Verfasst von Kuenyoul Park und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycoplasma pneumoniae is a leading atypical cause of community-acquired pneumonia in children and adults, and the prevalence of resistance to macrolides, the recommended first-line agents, varies markedly by region. Since the fastidious growth of M. pneumoniae makes phenotypic antimicrobial susceptibility testing impractical for routine use, clinical microbiology laboratories have focused on 23S rRNA gene-targeted molecular detection. This mini-review examines the molecular mechanisms of macrolide resistance, laboratory detection strategies, global epidemiology, and clonal dynamics revealed by molecular typing. Macrolide resistance is primarily driven by point mutations in domain V of the 23S rRNA gene, with A2063G accounting for most mutations worldwide, and A2064G being reported less frequently. Resistance in Korea rose from 2.9% in 2003 to 87.2% in a 2015 pediatric cohort, with subsequent studies reporting persistently high rates of approximately 78-87%. Earlier molecular typing studies suggest that this high resistance burden has been associated, at least in part, with the expansion of sequence type (ST) 3 and ST14 lineages. In contrast, Japan and Taiwan showed sharp declines following reductions in macrolide prescribing and P1 genotype turnover. Following the COVID-19 pandemic, a strong resurgence centered in East Asia, the possible global dispersal of ST3 and ST14 to Australia, Iran, and Canada, and the impact of co-circulation with influenza H3N2 have been reported. Real-time polymerase chain reaction (PCR) with simultaneous detection of 23S rRNA gene mutations and targeted metagenomic sequencing are emerging as next-generation surveillance tools. In summary, clinical microbiology laboratories should integrate M. pneumoniae detection with 23S rRNA gene resistance mutation detection using molecular assays and strengthen typingbased surveillance, thereby responding actively to the changing dynamics in East Asia and contributing to antimicrobial stewardship.

Zitieren

APA

Park, K., & Sung, H. (2026). Macrolide-resistant Mycoplasma pneumoniae: laboratory diagnosis and epidemiology. Annals of Clinical Microbiology, 29(3), 10-10. https://doi.org/10.5145/acm.2026.29.3.10

Vancouver

Park K, Sung H. Macrolide-resistant Mycoplasma pneumoniae: laboratory diagnosis and epidemiology. Annals of Clinical Microbiology. 2026;29(3):10-10. doi:10.5145/acm.2026.29.3.10

BibTeX
@article{Park2026,
  author = {Park, Kuenyoul and Sung, Heungsup},
  title = {Macrolide-resistant Mycoplasma pneumoniae: laboratory diagnosis and epidemiology},
  journal = {Annals of Clinical Microbiology},
  year = {2026},
  volume = {29},
  number = {3},
  pages = {10--10},
  doi = {10.5145/acm.2026.29.3.10}
}
Kostenlos starten →